title: Cyclosporine toxicity: the effect of combined therapy using cyclosporine, azathioprine, and prednisone.
abstract: Forty-nine patients among 360 who received renal transplants under cyclosporine (CsA)/prednisone (Pred) immunosuppression required alteration of the immunosuppressive regimen because of intractable nephrotoxicity. Twenty-five patients, converted totally to azathioprine (Aza)/Pred, suffered intractable nephrotoxicity with no associated evidence suggesting ongoing rejection. The results with Aza/Pred conversion were disappointing because of an unacceptably high incidence of rejection and allograft loss. Twenty-four patients with intractable CsA nephrotoxicity were, therefore, treated using an alternative approach combining Aza with aggressive CsA dose reduction, and continued Pred therapy. All patients tolerated initiation of Aza without complication; allograft rejection was not common. Renal function improved for 23 of the 24 (96%) CsA/Aza/Pred patients with mean serum creatinine levels falling from 3.5 +/- 0.5 mg/dL to 2.2 +/- 0.4 mg/dL after a mean follow-up of 14 months (P less than .001). Among 18 patients observed at least 12 months, seven (39%) enjoyed serum creatinine values less than or equal to 2 mg/dL. Nine CsA/Aza/Pred-treated patients (37.5%) required hospitalization because of infectious complications, all of which resolved with temporary reduction of immunosuppression and specific antimicrobial therapy when indicated. One patient sustained acute allograft rejection as a result of patient noncompliance, and one patient on a seemingly appropriate CsA/Aza/Pred dose responded initially to steroid pulse antirejection therapy; however, renal function again worsened. Two patients developed progressive renal dysfunction due to chronic rejection, and returned to dialysis 13 and 17 months, respectively, following initiation of CsA/Aza/Pred. Overall, the actuarial graft survival for CsA/Aza/Pred-treated patients was 100% at 1 year, and 84% at 2 years.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: M I
authors.initials: MI
authors.lastname: Lorber
authors.forename: S M
authors.initials: SM
authors.lastname: Flechner
authors.forename: C T
authors.initials: CT
authors.lastname: Van Buren
authors.forename: K
authors.initials: K
authors.lastname: Sorensen
authors.forename: R H
authors.initials: RH
authors.lastname: Kerman
authors.forename: B D
authors.initials: BD
authors.lastname: Kahan
mesh_terms: D000328:Adult; D001379:Azathioprine / Q000008:administration & dosage*; D003524:Cyclosporins / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000188:drug therapy; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009399:Nephrons; D011241:Prednisone / Q000008:administration & dosage*
chemical_list: D003524:Cyclosporins; D001379:Azathioprine; D011241:Prednisone